A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

Inclusion Criteria

• •Completion of the planned 12-month core trial, (NCT00390858).
• •Female patients who have reached menarche and who were sexually active were to use double-barrier contraception, oral contraceptive plus barrier contraceptive, or must have undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation.
• •Written informed consent obtained from the patient, and/or from the parent or legal guardian in accordance with the national legislation.